Evolent Health Inc. (EVH)
NYSE:EVH
Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$2.84
<$0.01(0.08%)
At close: 4:00 PM EST
$2.84
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$2.10 - $12.07
Previous CloseN/A
Volume268.11K
Average Volume (3M)2.91M
Market Cap
$432.13M
Enterprise Value$1.26B
Total Cash (Recent Filing)$151.86M
Total Debt (Recent Filing)$989.70M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 07, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding111,638,336
10 Day Avg. Volume3,121,893
30 Day Avg. Volume2,908,270
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap2.92
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda-3.49
Forecast
1Y Price Target
$5.14Price Target Upside80.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.14
Revenue Forecast (FY)$2.49B
Bulls Say, Bears Say
Bulls Say
Contract Wins And Managed Care DemandLarge performance-suite and risk contract wins demonstrate robust managed-care demand, creating embedded earnings potential and clearer revenue visibility that offsets revenue lost from divestitures.
Margin Improvement InitiativesMaturing performance-suite contracts, narrower risk corridors, and AI-driven cost controls are poised to improve margins and adjusted EBITDA as the business scales, reducing result volatility.
Revenue OutlookAnalyst's raised revenue forecasts reflect strong underlying demand and a deep sales pipeline that could drive top-line growth and support valuation expansion.
Bears Say
Conservative Reserving ImpactConservative reserve booking for new performance-suite contracts is depressing reported profitability and could keep earnings below investor expectations until reserves are released.
Execution And Forecasting RiskInconsistent execution and a history of missed guidance raise concerns about forecasting credibility, making the stock dependent on sustained operational outperformance to restore investor confidence.
Membership And ACA ChurnDeclining exchange and ACA membership from subsidy changes and plan exits is shrinking the revenue base for certain contracts and reducing expected profitability.
Evolent Health News
EVH FAQ
What was Evolent Health Inc.’s price range in the past 12 months?
Evolent Health Inc. lowest stock price was $2.10 and its highest was $12.06 in the past 12 months.
What is Evolent Health Inc.’s market cap?
Evolent Health Inc.’s market cap is $432.13M.
When is Evolent Health Inc.’s upcoming earnings report date?
Evolent Health Inc.’s upcoming earnings report date is May 07, 2026 which is in 7 days.
How were Evolent Health Inc.’s earnings last quarter?
Evolent Health Inc. released its earnings results on Feb 24, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.051 by $0.029.
Is Evolent Health Inc. overvalued?
According to Wall Street analysts Evolent Health Inc.’s price is currently Undervalued.
Does Evolent Health Inc. pay dividends?
Evolent Health Inc. does not currently pay dividends.
What is Evolent Health Inc.’s EPS estimate?
Evolent Health Inc.’s EPS estimate is -0.05.
How many shares outstanding does Evolent Health Inc. have?
Evolent Health Inc. has 111,638,336 shares outstanding.
What happened to Evolent Health Inc.’s price movement after its last earnings report?
Evolent Health Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of $0.051. Following the earnings report the stock price went up 22.656%.
Which hedge fund is a major shareholder of Evolent Health Inc.?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.14 (80.86% Upside)
$5.14 (80.86% Upside)
Blogger Sentiment
Neutral
EVH Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 420.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.30%
12-Months-Change
Fundamentals
Return on Equity
-69.22%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Evolent Health Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: strong top-line growth prospects (mid-2026 revenue growth target ~30%), large new Performance Suite contracts (including a significant Highmark engagement), solid 2025 MER improvement and realized cost/AI savings support long-term margin tailwinds. However, near-term headwinds are meaningful — conservative reserving for new launches (new cohort at ~103% MER), a $40M exchange-related revenue/EBITDA hit from regulatory/market shifts, administrative churn and limited free cash flow in 2026. Management emphasized that 2026 adjusted EBITDA will be back-end weighted and articulated a clear path to improved margins and cash flow as contracts mature, supporting a balanced long-term outlook despite near-term pressure.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.14
▲(80.86% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
16.71% Mutual Funds
0.54% Other Institutional Investors
68.46% Public Companies and
Individual Investors